Pascal Bamford - 19 Nov 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Clinical Officer
Signature: /s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 19 Nov 2024
Net transactions value: $0
Form type: 4
Filing time: 21 Nov 2024, 17:20:02 UTC
Previous filing: 03 Sep 2024
Next filing: 04 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+87,500	+71%	$0.000000	210,258	19 Nov 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is six months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.

Content

The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is six months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.

Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.